244 related articles for article (PubMed ID: 30714520)
1. Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.
Dash A; Das T; Knapp FFR
Curr Med Chem; 2020; 27(19):3187-3249. PubMed ID: 30714520
[TBL] [Abstract][Full Text] [Related]
2. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
3. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.
Goyal J; Antonarakis ES
Cancer Lett; 2012 Oct; 323(2):135-46. PubMed ID: 22521546
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
6. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Rubini G; Nicoletti A; Rubini D; Asabella AN
Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
[TBL] [Abstract][Full Text] [Related]
7. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.
Lam MG; de Klerk JM; van Rijk PP; Zonnenberg BA
Anticancer Agents Med Chem; 2007 Jul; 7(4):381-97. PubMed ID: 17630915
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
9. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.
Tomblyn M
Cancer Control; 2012 Apr; 19(2):137-44. PubMed ID: 22487976
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide therapy and integrated protocols for bone metastases.
Chiacchio S; Mazzarri S; Lorenzoni A; Nyakale N; Boni G; Borsò E; Alsharif A; Grosso M; Manca G; Greco C; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):431-47. PubMed ID: 21738116
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
12. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
13. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
14. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
15. Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Bouman-Wammes EW; de Klerk JMH; Bloemendal HJ; Van Dodewaard-de Jong JM; Lange R; Ter Heine R; Verheul HMW; Van den Eertwegh AJM
Clin Genitourin Cancer; 2019 Apr; 17(2):e281-e292. PubMed ID: 30555024
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
17. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
18. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Ahmadzadehfar H; Essler M; Rahbar K; Afshar-Oromieh A
PET Clin; 2018 Oct; 13(4):491-503. PubMed ID: 30219184
[TBL] [Abstract][Full Text] [Related]
19. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Pandit-Taskar N; Larson SM; Carrasquillo JA
J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
[TBL] [Abstract][Full Text] [Related]
20. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
